文献速递心力衰竭与心肌病

暴发性心肌炎出院后远期预后及心功能受损预测因素

[Long term prognosis of fulminant myocarditis and predictors related to impaired cardiac function post discharge].
PubMed 文献 · Zhonghua Xin Xue Guan Bing Za Zhi · 2022-01-01

该回顾性研究纳入125例急性心肌炎患者(FM组66例,NFM组59例),比较生存出院后远期预后。随访12(6,24)个月发现,FM组LVEF持续<55%和左心室增大的发生率均高于NFM组;住院期间LVEF恢复时间长是FM患者出院后心功能受损的独立危险因素(HR=1.199,95%CI 1.023~1.406,P=0.025)。

要点

  • FM患者出院后LVEF持续<55%和左心室增大发生率高于NFM患者。
  • 住院期间LVEF恢复时间长是FM出院后心功能受损独立危险因素。
  • FM患者出院后仍需长期监测心功能及左心室结构。

核心结论

  • 生存出院的FM患者LVEF持续降低及左心室增大的比例高于NFM患者。
  • 住院期间LVEF恢复时间长是FM患者出院后心功能受损的独立危险因素(HR=1.199,95%CI 1.023~1.406,P=0.025)。

研究设计与样本

  • 回顾性研究,连续纳入2017年1月至2020年12月于同济医院住院的急性心肌炎患者125例,其中FM组66例、NFM组59例。
  • 根据LVEF是否持续<55%将FM组进一步分为心功能正常组和心功能受损组。
  • 出院后第1、3、6和12个月返院随访,以后每年随访1次。

主要发现

  • FM组住院期间LVEF最低值<55%者比例高于NFM组(P<0.01),住院期间LVEF恢复时间较长(P<0.01)。
  • 两组出院时LVEF<55%者比例相当(P=0.071)。
  • 随访12(6,24)个月,FM组1例(1.5%)心原性死亡,16例(24.2%)LVEF持续<55%,8例(12.1%)左心室增大;NFM组3例(5.1%)LVEF持续<55%,1例(1.7%)左心室增大。
  • FM组LVEF持续<55%发生率高于NFM组(P=0.003),左心室增大比率亦高于NFM组(P=0.024)。
  • FM组亚组分析:心功能受损组起病至入院时间更短(P=0.011)、出院时LVEF<55%占比更高(P=0.039)、接受冠状动脉造影比例更高(P=0.014)、住院期间LVEF恢复时间更长(P=0.036)。

关键数值与推荐

  • 心功能受损定义为LVEF<55%。
  • 多因素Cox回归显示住院期间LVEF恢复时间长是FM患者出院后心功能受损的独立危险因素(HR=1.199,95%CI 1.023~1.406,P=0.025)。

临床怎么用

  • FM患者出院后应长期随访LVEF和左心室大小,尤其住院期间LVEF恢复时间较长者。
  • 出院时LVEF<55%的FM患者可能需更密切的心功能监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To compare the long-term prognosis of fulminant myocarditis (FM) and non-fulminant myocarditis (NFM) patients who survived and discharged from hospital, and to explore the factors associated with the long-term prognosis and impaired cardiac function. Methods: This study was a retrospective study. Consecutive patients with acute myocarditis hospitalized in Tongji Hospital from January 2017 to December 2020 were enrolled and divided into FM group and NFM group according to the type of myocarditis. Then, patients in the FM group were further divided into normal cardiac function group and impaired cardiac function group according the left ventricular ejection fraction (LVEF). All patients with acute myocarditis were treated with antiviral, immunomodulatory, immunosuppressive medications and symptomatic and supportive treatment, while FM patients were treated with comprehensive treatment plan. Clinical data at admission of enrolled patients were collected through the electronic medical record system. Patients were clinically followed-up at 1, 3, 6 and 12 months, then once a year after discharge by clinical visit. The primary endpoints included major cardiovascular events, impaired cardiac function was defined by LVEF<55%. Kaplan-Meier survival curve was used to analyze the occurrence of LVEF<55% and left ventricular enlargement during the follow-up of patients in FM group and NFM group, and Log-rank test was used for comparison between groups. Cox regression model was used to analyze the risk factors of impaired cardiac function in patients with FM during follow-up. Results: A total of 125 patients with acute myocarditis were enrolled (66 in FM group and 59 in NFM group). Compared with NFM group, the proportion of FM patients with the lowest LVEF<55% during hospitalization was higher (P<0.01), and the recovery time of normal LVEF during hospitalization was longer (P<0.01). The proportion of LVEF<55% at discharge was similar between the two groups (P=0.071). During the follow-up of 12 (6, 24) months, 1 patient (1.5%) died due to cardiac reasons in FM group after discharge, 16 patients (24.2%) had sustained LVEF<55% after discharge, and 8 patients (12.1%) had left ventricular enlargement. In NFM group, 3 patients (5.1%) had sustained LVEF<55%, and 1 patient (1.7%) had left ventricular enlargement. Kaplan-Meier survival curve analysis showed that the incidence of sustained LVEF<55% in FM group was higher than that in NFM group (P=0.003), and the incidence of left ventricular enlargement was also higher than that in NFM group (P=0.024). Subgroup analysis of patients in the FM group showed that, compared with the normal cardiac function group, the time from onset to admission was shorter (P=0.011), the proportion of LVEF<55% at discharge was higher (P=0.039), the proportion of coronary angiography was higher (P=0.014), and the LVEF recovery time during hospitalization was longer (P=0.036) in FM patients with impaired cardiac function. Multivariate Cox regression analysis showed that longer LVEF recovery time during hospitalization was an independent risk factor for cardiac function impairment after discharge of FM patients (HR=1.199, 95%CI 1.023-1.406, P=0.025). Conclusions: The incidence of reduced LVEF is significantly higher in FM patients than that in NFM patients. Longer LVEF recovery time during hospitalization is an independent risk factor for cardiac function impairment in FM patients after discharge. 目的: 比较生存出院的暴发性心肌炎(FM)和非暴发性心肌炎(NFM)患者的远期预后,并分析FM患者出院后心功能受损的危险因素。 方法: 该研究为回顾性研究。连续纳入2017年1月至2020年12月于华中科技大学同济医学院附属同济医院心血管内科住院的急性心肌炎患者,根据心肌炎的类型分为FM组和NFM组。然后,根据左心室射血分数(LVEF)是否持续<55%,将FM组患者进一步分为心功能正常组和心功能受损组。所有急性心肌炎患者均给予抗病毒、免疫调节、免疫抑制及对症支持治疗,FM患者均采用“综合救治方案”进行救治。通过电子病历系统收集入选患者基线(入院时)临床资料。患者出院后第1、3、6和12个月返院随访,以后每年随访1次。主要观察终点包括主要不良心脑血管事件、LVEF持续<55%和左心室增大。采用Kaplan-Meier生存曲线分析FM组及NFM组患者随访过程中发生LVEF持续<55%及左心室持续增大的情况,并采用Log-rank检验进行组间比较。采用Cox回归模型分析FM患者心功能受损的危险因素。 结果: 共入选急性心肌炎患者 125例,其中FM组66例、NFM组59例。与NFM 组比较,FM组患者住院期间LVEF最低值<55%者比例较高(P<0.01)、住院期间LVEF恢复时间较长(P<0.01)。两组患者出院时LVEF<55%者比例相当(P=0.071)。随访12(6,24)个月,FM组1例(1.5%)患者出院后发生心原性死亡,16例(24.2%)患者出院后LVEF持续<55%,8例(12.1%)患者左心室增大;NFM组3例(5.1%)患者LVEF持续<55%,1例(1.7%)患者左心室增大。Kaplan-Meier生存曲线分析结果显示,FM组患者LVEF持续<55%的发生率高于NFM组(P=0.003),左心室增大的比率亦高于NFM组(P=0.024)。FM组患者的亚组分析结果显示,与心功能正常组比较,心功能受损组起病至入院时间更短(P=0.011)、出院时LVEF<55%占比更高(P=0.039)、接受冠状动脉造影的比例更高(P=0.014)、住院期间LVEF恢复时间更长(P=0.036)。多因素Cox回归分析结果显示,住院期间LVEF恢复时间长是FM患者出院后心功能受损的独立危险因素(HR=1.199,95%CI 1.023~1.406,P=0.025)。 结论: 生存出院的FM患者发生LVEF持续降低及左心室增大的比例高于NFM患者。住院期间LVEF恢复时间长是FM患者出院后心功能受损的独立危险因素。.

来源:Zhonghua Xin Xue Guan Bing Za Zhi,查看原文。版权归原作者所有。

引用

  1. Jiang JG, Liu C, Cui GL, et al. [Long term prognosis of fulminant myocarditis and predictors related to impaired cardiac function post discharge]. Zhonghua Xin Xue Guan Bing Za Zhi. 2022. PMID: 35340145. doi:10.3760/cma.j.cn112148-20211206-01056

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。